56 related articles for article (PubMed ID: 36517084)
21. Evaluating the impact of early identification of asymptomatic brain metastases in metastatic renal cell carcinoma.
Parmar A; Ghosh S; Sahgal A; Lalani AA; Hansen AR; Reaume MN; Wood L; Basappa NS; Heng DYC; Graham J; Kollmannsberger C; Soulières D; Breau RH; Tanguay S; Kapoor A; Pouliot F; Bjarnason GA
Cancer Rep (Hoboken); 2023 Mar; 6(3):e1763. PubMed ID: 36517084
[TBL] [Abstract][Full Text] [Related]
22. Impact of Systemic Therapy in Metastatic Renal-Cell Carcinoma Patients With Synchronous and Metachronous Brain Metastases.
Parmar A; Soliman H; Sahgal A; Bjarnason GA
Clin Genitourin Cancer; 2020 Jun; 18(3):e224-e232. PubMed ID: 32139300
[TBL] [Abstract][Full Text] [Related]
23. Timing of brain metastases development in metastatic renal cell cancer patients treated with targeted therapies and survival outcomes: An Australian multicenter study.
Ha FJ; Spain L; Dowling A; Kwan EM; Pezaro C; Day D; Chia PL; Tran B; Pook D; Weickhardt AJ
Asia Pac J Clin Oncol; 2019 Oct; 15(5):e97-e102. PubMed ID: 30701671
[TBL] [Abstract][Full Text] [Related]
24. Outcomes of complete metastasectomy in metastatic renal cell carcinoma patients: The Canadian Kidney Cancer information system experience.
Dragomir A; Nazha S; Wood LA; Rendon RA; Finelli A; Hansen A; So AI; Kollmannsberger C; Basappa NS; Pouliot F; Soulières D; Heng DYC; Kapoor A; Tanguay S
Urol Oncol; 2020 Oct; 38(10):799.e1-799.e10. PubMed ID: 32778475
[TBL] [Abstract][Full Text] [Related]
25. Extracerebral metastases determine the outcome of patients with brain metastases from renal cell carcinoma.
Vogl UM; Bojic M; Lamm W; Frischer JM; Pichelmayer O; Kramer G; Haitel A; Kitz K; Harmankaya K; Zielinski CC; Schmidinger M
BMC Cancer; 2010 Sep; 10():480. PubMed ID: 20819239
[TBL] [Abstract][Full Text] [Related]
26. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update.
Ljungberg B; Albiges L; Abu-Ghanem Y; Bedke J; Capitanio U; Dabestani S; Fernández-Pello S; Giles RH; Hofmann F; Hora M; Klatte T; Kuusk T; Lam TB; Marconi L; Powles T; Tahbaz R; Volpe A; Bex A
Eur Urol; 2022 Oct; 82(4):399-410. PubMed ID: 35346519
[TBL] [Abstract][Full Text] [Related]
27. Prognosis of Incidental Brain Metastases in Patients With Advanced Renal Cell Carcinoma.
Kotecha RR; Flippot R; Nortman T; Guida A; Patil S; Escudier B; Motzer RJ; Albiges L; Voss MH
J Natl Compr Canc Netw; 2021 Apr; 19(4):432-438. PubMed ID: 33578374
[TBL] [Abstract][Full Text] [Related]
28. Determining generalizability of the Canadian Kidney Cancer information system (CKCis) to the entire Canadian kidney cancer population.
Tajzler C; Tanguay S; Mallick R; Ahrens B; Ly TL; Breau RH; Basappa NS; Kapoor A; Heng DYC; Pouliot F; Finelli A; Lavallée LT; So AI; Drachenberg DE; Soulières D; Bjarnason GA; Richard PO; Maloni R; Power NE; Haan M; Wood LA
Can Urol Assoc J; 2020 Oct; 14(10):E499-E506. PubMed ID: 33275557
[TBL] [Abstract][Full Text] [Related]
29. Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019.
Hotte SJ; Kapoor A; Basappa NS; Bjarnason G; Canil C; Conter HJ; Czaykowski P; Graham J; Gray S; Heng DYC; Karakiewicz PI; Kollmannsberger C; Lalani AA; North SA; Patenaude F; Soulières D; Violette P; Winquist E; Wood LA; Dudani S; Maloni R; Reaume MN;
Can Urol Assoc J; 2019 Oct; 13(10):343-354. PubMed ID: 31603413
[No Abstract] [Full Text] [Related]
30. Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study.
Flippot R; Dalban C; Laguerre B; Borchiellini D; Gravis G; Négrier S; Chevreau C; Joly F; Geoffrois L; Ladoire S; Mahammedi H; Rolland F; Gross-Goupil M; Deluche E; Priou F; Laramas M; Barthélémy P; Narciso B; Houedé N; Culine S; Oudard S; Chenot M; Tantot F; Chabaud S; Escudier B; Albiges L
J Clin Oncol; 2019 Aug; 37(23):2008-2016. PubMed ID: 31194611
[TBL] [Abstract][Full Text] [Related]
31. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update.
Ljungberg B; Albiges L; Abu-Ghanem Y; Bensalah K; Dabestani S; Fernández-Pello S; Giles RH; Hofmann F; Hora M; Kuczyk MA; Kuusk T; Lam TB; Marconi L; Merseburger AS; Powles T; Staehler M; Tahbaz R; Volpe A; Bex A
Eur Urol; 2019 May; 75(5):799-810. PubMed ID: 30803729
[TBL] [Abstract][Full Text] [Related]
32. Stereotactic Radiosurgery for Multiple Brain Metastases From Renal-Cell Carcinoma.
Wardak Z; Christie A; Bowman A; Stojadinovic S; Nedzi L; Barnett S; Patel T; Mickey B; Whitworth T; Hannan R; Brugarolas J; Timmerman R
Clin Genitourin Cancer; 2019 Apr; 17(2):e273-e280. PubMed ID: 30595522
[TBL] [Abstract][Full Text] [Related]
33. Improved Survival Outcomes for Kidney Cancer Patients With Brain Metastases.
Bowman IA; Bent A; Le T; Christie A; Wardak Z; Arriaga Y; Courtney K; Hammers H; Barnett S; Mickey B; Patel T; Whitworth T; Stojadinovic S; Hannan R; Nedzi L; Timmerman R; Brugarolas J
Clin Genitourin Cancer; 2019 Apr; 17(2):e263-e272. PubMed ID: 30538068
[TBL] [Abstract][Full Text] [Related]
34. Canadian Urological Association guideline for followup of patients after treatment of non-metastatic renal cell carcinoma.
Kassouf W; Monteiro LL; Drachenberg DE; Fairey AS; Finelli A; Kapoor A; Lattouf JB; Leveridge MJ; Power NE; Pouliot F; Rendon RA; Sabbagh R; So AI; Tanguay S; Breau RH
Can Urol Assoc J; 2018 Aug; 12(8):231-238. PubMed ID: 30139427
[No Abstract] [Full Text] [Related]
35. Utilization of Stereotactic Radiosurgery for Renal Cell Carcinoma Brain Metastases.
Haque W; Verma V; Butler EB; Teh BS
Clin Genitourin Cancer; 2018 Aug; 16(4):e935-e943. PubMed ID: 29680768
[TBL] [Abstract][Full Text] [Related]
36. Gamma knife stereotactic radiosurgery for renal cell carcinoma and melanoma brain metastases-comparison of dose response.
Lin HY; Watanabe Y; Cho LC; Yuan J; Hunt MA; Sperduto PW; Abosch A; Watts CR; Lee CK
J Radiosurg SBRT; 2013; 2(3):193-207. PubMed ID: 29296362
[TBL] [Abstract][Full Text] [Related]
37. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial.
Brown PD; Ballman KV; Cerhan JH; Anderson SK; Carrero XW; Whitton AC; Greenspoon J; Parney IF; Laack NNI; Ashman JB; Bahary JP; Hadjipanayis CG; Urbanic JJ; Barker FG; Farace E; Khuntia D; Giannini C; Buckner JC; Galanis E; Roberge D
Lancet Oncol; 2017 Aug; 18(8):1049-1060. PubMed ID: 28687377
[TBL] [Abstract][Full Text] [Related]
38. Impact of resection and systemic therapy on the survival of patients with brain metastasis of metastatic renal cell carcinoma.
Du Y; Pahernik S; Hadaschik B; Teber D; Duensing S; Jäger D; Hohenfellner M; Grüllich C
J Neurooncol; 2016 Oct; 130(1):221-228. PubMed ID: 27538910
[TBL] [Abstract][Full Text] [Related]
39. Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial.
Brown PD; Jaeckle K; Ballman KV; Farace E; Cerhan JH; Anderson SK; Carrero XW; Barker FG; Deming R; Burri SH; Ménard C; Chung C; Stieber VW; Pollock BE; Galanis E; Buckner JC; Asher AL
JAMA; 2016 Jul; 316(4):401-409. PubMed ID: 27458945
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
